Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 11, 2019 - Issue
Submit an article Journal homepage
102
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Health care utilization and costs following amplified versus non-amplified molecular probe testing for symptomatic patients with suspected vulvovaginitis: a US commercial payer population

Stacey J Ackerman1 Covance Market Access Services Inc., San Diego, CA, USA, [email protected]Correspondence[email protected]
,
Tyler Knight2 Covance Market Access Services Inc., Gaithersburg, MD, USA
,
Peter M Wahl2 Covance Market Access Services Inc., Gaithersburg, MD, USA
&
Charles P Cartwright3 Center for Esoteric Testing, Laboratory Corporation of America Holdings, Burlington, NC, USA
Pages 179-189 | Published online: 20 Feb 2019

Figures & data

Figure 1 Patient selection criteria.

Abbreviations: AMP, amplified molecular probe test; NAMP, non-amplified molecular probe test; PS, propensity score; VV, vulvovaginitis.
Figure 1 Patient selection criteria.

Table 1 Baseline demographics and clinical characteristics of the cohorts before and after PS matching

Figure 2 Comparison of all-cause total medical expenditures for PS-matched patients. (A) Comparison of total medical expenditures (index date+ post-index period). (B) Comparison of medical expenditure components within the post-index period.

Notes: The index date is defined as the date of AMP or NAMP testing. The post-index period includes 182 days following the index date; the post-index period excludes the index date. Mean expenditures for diagnostic testing for VV on the index date were $116 and $57 for the AMP and NAMP cohorts, respectively (P<0.0001). aP<0.0001.
Abbreviations: AMP, amplified molecular probe test; ED, emergency department; NAMP, non-amplified molecular probe test; PCP, primary care physician; PS, propensity score; VV, vulvovaginitis.
Figure 2 Comparison of all-cause total medical expenditures for PS-matched patients. (A) Comparison of total medical expenditures (index date+ post-index period). (B) Comparison of medical expenditure components within the post-index period.

Table S1 Current procedure terminology codes for identifying testing cohorts

Table S2 Diagnosis codes and drugs for identifying pre-index vulvovaginitis

Table S3 Current procedure terminology codes for vulvovaginitis diagnostic tests

Table S4 Diagnosis codes for malignancy

Table S5 Diagnosis codes for pregnancy

Table S6 Diagnosis codes for preterm labor and delivery

Table S7 Comorbid condition diagnosis codes and drugs of interest

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.